GT Biopharma CEO says ‘pleased with progress’ with TriKE platform

GT Biopharma announced it will present two poster presentations at the Society for Immunotherapy of Cancer’s 37th Annual Meeting, or SITC 2022, to be held in Boston, Massachusetts and virtually on November 8-12. The two posters highlight tri-specific killer engagers for the treatment of mesothelioma and prostate cancer. "We are pleased with the progress that has been made in assessing the broad applicability of our novel TriKE platform across solid tumors" said Michael Breen, Executive Chairman and Interim CEO of GT Biopharma. "Our TriKE structure consisting of an anti-CD16 nanobody which binds to NK cells and triggers antibody directed cell-mediated cytotoxicity, IL-15 cross-linker that binds to NK cells inducing self-sustaining expansion and extended survival and an anti-tumor associated antigen which binds to well-known tumor antigens. The TriKE modular platform allows for targeting multiple tumor-associated antigens. As such, we remain excited in our progress to date while looking forward to submitting an Investigational New Drug application in 2023 for lead assets GTB-3650 targeting CD33 positive tumors and GTB-5550 targeting B7H3 positive tumors, respectively."